Nilotinib Effects on Safety, Tolerability, and Potential Biomarkers in Parkinson Disease
Authors:
Open Access
- 1 March 2020
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Neurology
- Vol. 77 (3) , 309-317
Abstract
Parkinson disease (PD) is the second most common neurodegenerative disorder worldwide, causing motor and nonmotor symptoms, loss of dopamine, and accumulation of misfolded α-synuclein.1-3 Nilotinib hydrochloride is a multikinase inhibitor that preferentially targets Abelson (Abl)4-6 and discoidin domain receptors4-7 and effectively reduces misfolded proteins in several models of neurodegeneration.7 Nilotinib is approved in the United States for treatment of Philadelphia chromosome‒positive chronic myeloid leukemia at oral dosages of 300 mg twice daily.4-6 Several studies reported that low doses of nilotinib enter the brain and degrade α-synuclein and tau in animal models of neurodegeneration.7-11 A previous study suggested that nilotinib may increase dopamine metabolism and potentially treat motor and nonmotor symptoms of PD.12Keywords
This publication has 26 references indexed in Scilit:
- Parkin Ubiquitinates Tar-DNA Binding Protein-43 (TDP-43) and Promotes Its Cytosolic Accumulation via Interaction with Histone Deacetylase 6 (HDAC6)Journal of Biological Chemistry, 2013
- BCR-ABL1 Kinase: Hunting an Elusive Target with New WeaponsChemistry & Biology, 2011
- Elevated Levels of α-Synuclein Oligomer in the Cerebrospinal Fluid of Drug-Naïve Patients with Parkinson's DiseaseJournal of Clinical Neurology, 2011
- Evidence that Resistance to Nilotinib May Be Due to BCR-ABL, Pgp, or Src Kinase OverexpressionCancer Research, 2008
- Nilotinib: A second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemiaClinical Therapeutics, 2008
- Detection of oligomeric forms of α‐synuclein protein in human plasma as a potential biomarker for Parkinson's diseaseThe FASEB Journal, 2006
- Does levodopa slow or hasten the rate of progression of Parkinson’s disease?Journal of Neurology, 2005
- Catecholamine Metabolism: A Contemporary View with Implications for Physiology and MedicinePharmacological Reviews, 2004
- Alpha-synuclein and neurodegenerative diseasesNature Reviews Neuroscience, 2001
- α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodiesProceedings of the National Academy of Sciences, 1998